{"id":724725,"date":"2023-01-20T08:05:21","date_gmt":"2023-01-20T13:05:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/"},"modified":"2023-01-20T08:05:21","modified_gmt":"2023-01-20T13:05:21","slug":"aptorum-group-announces-1-for-10-reverse-stock-split","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/","title":{"rendered":"Aptorum Group Announces 1-for-10 Reverse Stock Split"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Aptorum Group Announces 1-for-10 Reverse Stock Split<\/b><\/p>\n<p>NEW YORK &amp; LONDON &amp; PARIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:\n<\/p>\n<p>\nAptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the \u201cCompany\u201d) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company&#8217;s Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company\u2019s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company\u2019s Class B Ordinary Shares shall also be split on a 1-for-10 reverse basis.\n<\/p>\n<p>\nAt the Company&#8217;s Annual General Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) held on December 21, 2022, the Company&#8217;s shareholders approved grating the Company\u2019s board of directors the right to implement a reverse stock split in which every 10 Class A Ordinary Shares, par value of US$1.00 per share, in the authorized share capital of the Company (including issued and unissued share capital) be consolidated into 1 Class A Ordinary Share, par value of US$10.00 per share, and that every 10 Class B Ordinary Shares, par value of US$1.00 per share in the authorized share capital of the Company (including issued and unissued share capital) be consolidated into 1 Class B Ordinary Share, par value of US$10.00 per share. On January 6, 2023, the Company\u2019s Board of Directors approved the 1-for-10 reverse split to be effective as of January 23, 2023.\n<\/p>\n<p>\nThe Company&#8217;s Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Global Market. The Company has until May 16, 2023 to comply with this requirement. To comply with this requirement, the closing bid price of the Company&#8217;s Class A Ordinary Shares must be at least $1.00 per share for a minimum of 10 consecutive business days prior to May 16, 2023. There is no guarantee the Company will meet the minimum bid price requirement.\n<\/p>\n<p>\nThe Company&#8217;s shares of Class A Ordinary Shares will continue to trade on the NASDAQ under the symbol &#8220;APM.&#8221; The new CUSIP number for the Company&#8217;s Class A Ordinary Shares post-reverse stock split is G6096M 114.\n<\/p>\n<p>\nUpon the effectiveness of the reverse stock split, every 10 shares of the Company&#8217;s issued and outstanding Class A Ordinary Shares will automatically be converted into one share of Class A Ordinary Shares. Any fraction of a share of common stock that would be created as a result of the reverse stock split be rounded up to the next whole share.\n<\/p>\n<p><b>About Aptorum Group<\/b><\/p>\n<p>\nAptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 (MRSA) and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell<sup>\u00ae<\/sup> nutraceutical (menopause). The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore\u2019s Agency for Science, Technology and Research.\n<\/p>\n<p>\nFor more information about Aptorum Group, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aptorumgroup.com&amp;esheet=53285271&amp;newsitemid=20230120005107&amp;lan=en-US&amp;anchor=www.aptorumgroup.com&amp;index=1&amp;md5=5e8336e351214473f6726ce399ecfdad\">www.aptorumgroup.com<\/a>.\n<\/p>\n<p><b>Disclaimer and Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.\n<\/p>\n<p>\nThis press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201ccould,\u201d \u201cintends,\u201d \u201ctarget,\u201d \u201cprojects,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company\u2019s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group\u2019s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorit\u00e9 des March\u00e9s Financiers visa n\u00b020-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.\n<\/p>\n<p>\nThis announcement is not a prospectus within the meaning of the Regulation (EU) n\u00b02017\/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n\u00b02019\/980 of 14 March 2019 and n\u00b02019\/979 of 14 March 2019.\n<\/p>\n<p>\nThis press release is provided \u201cas is\u201d without any representation or warranty of any kind.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230120005107\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230120005107\/en\/<\/a><\/span><\/p>\n<p>\nAptorum Group Limited<br \/>\n<br \/>Investor Relations Department<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor.relations@aptorumgroup.com\">investor.relations@aptorumgroup.com<br \/>\n<\/a><br \/>+44 20 80929299\n<\/p>\n<p>\nRedchip \u2013 Financial Communications United States<br \/>\n<br \/>Investor relations<br \/>\n<br \/>Craig Brelsford<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:craig@redchip.com\">craig@redchip.com<br \/>\n<\/a><br \/>+1 407 571 0902\n<\/p>\n<p>\nActifin \u2013 Financial Communications Europe<br \/>\n<br \/>Investor relations<br \/>\n<br \/>Ghislaine Gasparetto<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ggasparetto@actifin.fr\">ggasparetto@actifin.fr<br \/>\n<\/a><br \/>+33 1 56 88 11 22\n<\/p>\n<p><b>KEYWORDS:<\/b> North America France United States United Kingdom Europe New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Clinical Trials Biotechnology General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230120005107\/en\/694651\/3\/aptorum_hori_HQ.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Aptorum Group Announces 1-for-10 Reverse Stock Split NEW YORK &amp; LONDON &amp; PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the \u201cCompany\u201d) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company&#8217;s Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company\u2019s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company\u2019s Class B Ordinary Shares shall also be split on a 1-for-10 reverse basis. At the Company&#8217;s Annual General Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) held on December 21, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aptorum Group Announces 1-for-10 Reverse Stock Split&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724725","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aptorum Group Announces 1-for-10 Reverse Stock Split NEW YORK &amp; LONDON &amp; PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the \u201cCompany\u201d) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company&#8217;s Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company\u2019s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company\u2019s Class B Ordinary Shares shall also be split on a 1-for-10 reverse basis. At the Company&#8217;s Annual General Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) held on December 21, &hellip; Continue reading &quot;Aptorum Group Announces 1-for-10 Reverse Stock Split&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T13:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aptorum Group Announces 1-for-10 Reverse Stock Split\",\"datePublished\":\"2023-01-20T13:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/\"},\"wordCount\":1033,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/\",\"name\":\"Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-01-20T13:05:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-announces-1-for-10-reverse-stock-split\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptorum Group Announces 1-for-10 Reverse Stock Split\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/","og_locale":"en_US","og_type":"article","og_title":"Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk","og_description":"Aptorum Group Announces 1-for-10 Reverse Stock Split NEW YORK &amp; LONDON &amp; PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the \u201cCompany\u201d) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the Company&#8217;s Class A Ordinary Shares, effective at 12:01 a.m. Eastern Time on January 23, 2023. The Company\u2019s Class A Ordinary Shares is expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The Company\u2019s Class B Ordinary Shares shall also be split on a 1-for-10 reverse basis. At the Company&#8217;s Annual General Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) held on December 21, &hellip; Continue reading \"Aptorum Group Announces 1-for-10 Reverse Stock Split\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-20T13:05:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aptorum Group Announces 1-for-10 Reverse Stock Split","datePublished":"2023-01-20T13:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/"},"wordCount":1033,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/","name":"Aptorum Group Announces 1-for-10 Reverse Stock Split - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-01-20T13:05:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230120005107r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-announces-1-for-10-reverse-stock-split\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aptorum Group Announces 1-for-10 Reverse Stock Split"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724725"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724725\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}